Glaukos Corporation (GKOS): Price and Financial Metrics

Glaukos Corporation (GKOS): $50.39

-0.98 (-1.91%)

POWR Rating

Component Grades














  • Quality is the dimension where GKOS ranks best; there it ranks ahead of 63.42% of US stocks.
  • GKOS's strongest trending metric is Sentiment; it's been moving down over the last 178 days.
  • GKOS ranks lowest in Growth; there it ranks in the 7th percentile.

GKOS Stock Summary

  • GKOS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 555.79 -- higher than 95.45% of US-listed equities with positive expected earnings growth.
  • Price to trailing twelve month operating cash flow for GKOS is currently 252.68, higher than 98.68% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 9.38, GLAUKOS CORP has a higher such ratio than 87.04% of stocks in our set.
  • Stocks that are quantitatively similar to GKOS, based on their financial statements, market capitalization, and price volatility, are EMKR, AAOI, WISA, VYNE, and MRIN.
  • GKOS's SEC filings can be seen here. And to visit GLAUKOS CORP's official web site, go to

GKOS Valuation Summary

  • GKOS's EV/EBIT ratio is -70.1; this is 777.29% lower than that of the median Healthcare stock.
  • GKOS's price/sales ratio has moved down 9.9 over the prior 88 months.

Below are key valuation metrics over time for GKOS.

Stock Date P/S P/B P/E EV/EBIT
GKOS 2022-09-09 9.3 4.8 -48.0 -70.1
GKOS 2022-09-08 9.6 4.9 -49.8 -72.5
GKOS 2022-09-07 9.4 4.8 -48.6 -70.9
GKOS 2022-09-06 7.9 4.1 -41.0 -60.9
GKOS 2022-09-02 8.1 4.1 -41.7 -61.7
GKOS 2022-09-01 8.1 4.1 -41.7 -61.7

GKOS Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -261.64%.
  • The year over year net cashflow from operations growth rate now stands at 630.63%.
  • Its 4 year price growth rate is now at 21.85%.
GKOS's revenue has moved up $63,105,000 over the prior 33 months.

The table below shows GKOS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 288.316 10.707 -55.801
2022-03-31 293.724 30.304 -27.747
2021-12-31 294.011 24.708 -49.593
2021-09-30 294.005 39.963 -38.369
2021-06-30 284.126 12.603 -60.347
2021-03-31 237.591 -5.711 -82.759

GKOS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GKOS has a Quality Grade of C, ranking ahead of 54.76% of graded US stocks.
  • GKOS's asset turnover comes in at 0.279 -- ranking 135th of 186 Medical Equipment stocks.
  • FONR, ATRC, and BSX are the stocks whose asset turnover ratios are most correlated with GKOS.

The table below shows GKOS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.279 0.747 -0.076
2021-03-31 0.236 0.681 -0.129
2020-12-31 0.238 0.592 -0.218
2020-09-30 0.243 0.595 -0.310
2020-06-30 0.291 0.632 -0.400
2020-03-31 0.432 0.731 -0.328

GKOS Stock Price Chart Interactive Chart >

Price chart for GKOS

GKOS Price/Volume Stats

Current price $50.39 52-week high $64.49
Prev. close $51.37 52-week low $33.33
Day low $49.39 Volume 436,000
Day high $50.82 Avg. volume 507,441
50-day MA $52.21 Dividend yield N/A
200-day MA $50.08 Market Cap 2.39B

Glaukos Corporation (GKOS) Company Bio

Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.

GKOS Latest News Stream

Event/Time News Detail
Loading, please wait...

GKOS Latest Social Stream

Loading social stream, please wait...

View Full GKOS Social Stream

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.

Yahoo | September 8, 2022

Analysts Are Bullish on Top Healthcare Stocks: Glaukos (GKOS), Verve Therapeutics (VERV)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Glaukos (GKOS – Research Report) and Verve Therapeutics (VERV – Research Report) with bullish sentiments. Glaukos (GKOS) In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Glaukos, with a price target of $67.00. The company's shares closed last Tuesday at $48.10. According to TipRanks.

Catie Powers on TipRanks | September 7, 2022

Glaukos (NYSE: GKOS) Shoots Up Following Positive Clinical Result

Glaukos Corp. (NYSE: GKOS) stock is surging on Wednesday as the pharmaceutical and ophthalmic medical technology announced positive topline data for both fast and slow release Phase 3 pivotal trials of iDose TR. iDose TR is the company's novel formulation of travoprost, a drug used to reduce Intraocular pressure (IOP) in the treatment of open-angle glaucoma (OAG) or ocular hypertension. The positive topline data indicates that it offers a suitable alternative to daily eye drop treatment. Glaukos stated that the Phase 3 trials achieved the pre-specified primary efficacy endpoint for both the fast and slow release models of iDose TR through three months.

Shrilekha Pethe on TipRanks | September 7, 2022

Why Glaukos Stock Zoomed Nearly 19% Higher Today

Glaukos (NYSE: GKOS), a specialty healthcare company that concentrates on eye disorders, enjoyed a very healthy pop in its share price on Wednesday. This followed the company's latest clinical update. The drug also demonstrated a favorable safety profile and was extremely well tolerated, Glaukos said.

Yahoo | September 7, 2022

Glaukos Shares Pop After Positive Data From Ocular Pressure Candidate

Glaukos Corporation (NASDAQ: GKOS) announced positive topline data for both Phase 3 trials of iDose TR. It achieved its pre-specified primary efficacy endpoints through 3 months and demonstrated excellent tolerability and a favorable safety profile through 12 months. The fast- and slow-release iDose TR arms achieved the primary efficacy endpoint of non-inferiority to the active comparator arm (topical timolol ophthalmic solution). Related: Glaukos Inks Licensing Pact For Rare Eye Disorder Treatm

Yahoo | September 7, 2022

Read More 'GKOS' Stories Here

GKOS Price Returns

1-mo 1.00%
3-mo 5.75%
6-mo -12.74%
1-year -0.42%
3-year -24.09%
5-year 55.05%
YTD 13.39%
2021 -40.95%
2020 38.17%
2019 -3.03%
2018 118.99%
2017 -25.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5885 seconds.